Source: Drug Target Review, May 2025
A new study from Central South University reveals how adenosine phosphate signalling shapes the tumour microenvironment in melanoma, offering a new biomarker for guiding personalised cancer treatment.
Malignant melanoma, a highly aggressive form of skin cancer, poses a significant global health threat due to its resistance to therapy and the complex, heterogeneous nature of its tumour microenvironment (TME). However, a new study by researchers at Central South University has found a biological mechanism that could transform treatment strategies: the role of adenosine phosphate signalling mediated by purinergic P2 receptors (P2Rs).